{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:47:03Z","timestamp":1791380823906,"version":"4.3.3"},"reference-count":13,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder. Hyperammonemia is a rare complication of VPA use, which can result in high morbidity and occasionally fatal encephalopathy. The scant literature on Valproate Induced Hyperammonemic Encephalopathy (VIHE) is characterized by acute onset of decreasing level of consciousness, drowsiness, lethargy which in rare instances can lead to seizures, stupor, coma, and persistent morbidity and cortical damage. Below we describe a case report of a patient with Bipolar I Disorder with no primary evidence of hepatic dysfunction that was initiated on VPA and olanzapine to address manic and psychotic symptoms. This patient subsequently developed elevated ammonia (NH4) levels that led to a reversible encephalopathy. This cautionary case report highlights the potential for a rare but serious complication from VPA, a medication increasingly used in both neurologic and neuropsychiatric settings. It is imperative that clinicians perform a thorough physical, neurological and diagnostic evaluation, routinely check NH4 and VPA levels when prescribing these agents and exercise caution when VPA is concomitantly prescribed with antipsychotics and cytochrome P450 inducing antiepileptic medications.<\/jats:p>","DOI":"10.64719\/pb.4355","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"40-44","source":"Crossref","is-referenced-by-count":2,"title":["Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report"],"prefix":"10.64719","volume":"47","author":[{"given":"Neel","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Fargason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badari","family":"Birur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Hayes J, Prah P, Nazareth I et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One. 2011;6(12):e28725.","DOI":"10.1371\/journal.pone.0028725"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Mishima N, Kagawa Y, Inoue Y. Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia. European Journal of Clinical Pharmacology. 2015;71(12):1517\u20131524.","DOI":"10.1007\/s00228-015-1939-3"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Tseng YL, Huang CR, Lin CH et al. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine. 2014;93(11):e66.","DOI":"10.1097\/MD.0000000000000066"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kifune A, Kubota F, Shibata N, Akata T, Kikuchi S. Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia. 2000;41(7):909\u2013912.","DOI":"10.1111\/j.1528-1157.2000.tb00263.x"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Finkelstein JE, Hauser ER, Leonard CO, Brusilow SW. Late-onset ornithine transcarbamylase deficiency in male patients. The Journal of Pediatrics. 1990;117(6):897\u2013902.","DOI":"10.1016\/S0022-3476(05)80129-5"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. The New England Journal of Medicine. 1984;310(23):1500\u20131505.","DOI":"10.1056\/NEJM198406073102304"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Aires CC, van Cruchten A, Ijlst L et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. Journal of Hepatology. 2011;55(2):426\u2013434.","DOI":"10.1016\/j.jhep.2010.11.031"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Twilla JD, Pierce AS. Hyperammonemic Encephalopathy due to Valproic Acid and Topiramate Interaction. Case Reports in Psychiatry. 2014;2014:410403.","DOI":"10.1155\/2014\/410403"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Chicharro AV, de Marinis AJ, Kanner AM. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Epilepsy & Behavior: E&B. 2007;11(3):361\u2013366.","DOI":"10.1016\/j.yebeh.2007.06.015"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Takahashi Y, Suzuki E et al. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Research. 2012;101(3):202\u2013209.","DOI":"10.1016\/j.eplepsyres.2012.04.001"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Takahashi Y, Imai K et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia. 2013;54(6):983\u2013989.","DOI":"10.1111\/epi.12125"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Carlson T, Reynolds CA, Caplan R. Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46(3):356\u2013361.","DOI":"10.1097\/chi.0b013e31802ed8b2"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Carr RB, Shrewsbury K. Hyperammonemia due to valproic acid in the psychiatric setting. The American Journal of Psychiatry. 2007;164(7):1020\u20131027.","DOI":"10.1176\/ajp.2007.164.7.1020"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:26:28Z","timestamp":1791314788000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/reversible-encephalopathy-due-to-valproic-acid-induced-hyperammonemia-in-a-patient-with-bipolar-i-disorder-a-cautionary-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4355","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}